| 王海燕,王秋慧,许 佩,徐丹丹,杨艳萍.格列美脲联合艾塞那肽治疗肥胖2型糖尿病的疗效观察[J].,2020,(8):1497-1500 |
| 格列美脲联合艾塞那肽治疗肥胖2型糖尿病的疗效观察 |
| Therapeutic Effect of Glimepiride Combined with Exenatide on the Obese Type 2 Diabetes Mellitus |
| 投稿时间：2019-08-05 修订日期：2019-08-28 |
| DOI：10.13241/j.cnki.pmb.2020.08.021 |
| 中文关键词: 肥胖 2型糖尿病 格列美脲 艾塞那肽 |
| 英文关键词: Obesity Type 2 diabetes Glimepiride Exenatide |
| 基金项目:国家重点研究发展计划项目 (2017YFC0112701)；解放军第四七四医院重点扶持科研项目(2018474004) |
|
| 摘要点击次数: 616 |
| 全文下载次数: 451 |
| 中文摘要: |
| 摘要 目的：探讨格列美脲联合艾塞那肽治疗肥胖2型糖尿病患者的临床效果。方法：选择2016年1月到2019年1月我院收治的82例肥胖2型糖尿病患者作为本次研究的对象，并将其随机的分为研究组和对照组，每组41例。研究组患者给予格列美脲联合艾塞那肽进行治疗，对照组患者给予格列美脲治疗，观察和比较两组患者治疗前后空腹血糖、餐后2 h血糖、空腹和餐后2 h血清C肽、身体质量指数（body mass index, BMI）、总胆固醇（total cholesterol, TC）、甘油三酯（triglyceride, TG）、低密度脂蛋白胆固醇（low density lipoprotein cholesterol, LDL-C）、高密度脂蛋白胆固醇（high density lipoprotein cholesterol, HDL-C）和糖化血红蛋白（glycosylated hemoglobin, HbAlC）水平的变化。结果：治疗后，两组患者空腹血糖、餐后2 h血糖水平均较治疗前明显降低，餐后2 h血清C肽水平均较治疗前明显升高，且研究组以上指标的改善程度较对照组更明显(P＜0.05)。两组患者治疗前后空腹血清C肽水平比较差异无统计学意义(P＞0.05)；治疗后，两组患者BMI、TC、TG、LDL-C和HbAlC水平均较治疗前显著降低，HDL-C水平明显升高，而研究组BMI、TC、TG、LDL-C和HbAlC水平显著低于对照组(P＜0.05)，HDL-C水平明显高于对照组(P＜0.05)。结论：格列美脲片联合艾塞那肽治疗肥胖2型糖尿病可有效的控制患者血糖，降低BMI，改善血脂水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical effects of glimepiride combined with exenatide in the treatment of obese type 2 diabetes. Methods: Eighty-two obese patients with type 2 diabetes admitted to our hospital from January 2016 to January 2019 were randomly divided into study group and control group, there were 41 cases in each group. The patients in study group were treated with glimepiride combination with exenatide, the patients in the control group were treated with glimepiride alone. The changes of levels of the fasting and 2h postprandial blood glucose, serum C-peptide, body mass index (BMI), total cholesterol (TC), triglyceride (triglyceride, TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and glycosylated hemoglobin (HbAlC) before and after treatment were observed and compared. Results: After treatment, the fasting blood glucose and the blood glucose levels in the two groups were significantly lower than those before treatment. The 2 h postprandial C-peptide level in serum was significantly higher than that before the treatment, and the improvement of the above indicators in the study group was more than that of the control group (P < 0.05). There was no significant difference in fasting serum C-peptide levels in the two groups before and after treatment (P>0.05). After treatment, the BMI, TC, TG, LDL-C and HbAlC levels in the two groups were significantly lower than those before treatment. The level of HDL-C was significantly increased. The levels of BMI, TC, TG, LDL-C and HbAlC in the study group were significantly lower than those in the control group (P<0.05), and the HDL-C level was significantly higher than the control group (P<0.05). Conclusion: Glimepiride tablets combined with exenatide in the treatment of obese type 2 diabetes can effectively control blood sugar, reduce BMI and improve blood lipid levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
